INTI

Healthcare Biotechnology

Inhibitor Therapeutics, Inc.

$0.10

-0.00 -2.00% today

Price History

Not enough data

Key Stats

Market Cap

17.13M

Avg Volume

6,762

EPS

-$0.02

52W High

$0.12

52W Low

$0.04

Div. Yield

0.0%

Valuation

P/B Ratio

-6.53

Margins

Gross Margin 0.0%

Operating Margin 0.0%

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Return on Assets

(92.7%)

Liquidity & Leverage

Current Ratio

3.35

Quick Ratio

2.95

Total Cash

515,758

Total Debt

47,828

About

Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies initially for basal cell carcinoma nevus syndrome (BCCNS) cancers by utilizing itraconazole; development of therapies initially for basal cell carcinoma (BCC) cancers; and SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. The company was founded in 1992 and is based in Tampa, Florida.

inhibitortx.com